The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, is looking for individuals to participate in clinical studies. Participating in clinical trials allows you to play an active role in research on the nature and causes of many disorders of the brain and nervous system, and to possibly help physician-scientists develop future treatments. The information below is designed to help you quickly learn about actively recruiting research studies for which you or someone you know may be eligible.

Description:

OBJECTIVES: - Determine the toxic effects and maximum tolerated dose (MTD) of interstitial interleukin-13 PE38QQR immunotoxin in patients with malignant glioma. - Determine the response rate, duration of response, time to response, overall survival, and time to progression in patients treated with this regimen. - Determine the toxic effects of this drug at the MTD in these patients. OUTLINE: This is a dose-escalation, multicenter study. Patients undergo stereotactic biopsy of brain tumor followed by CT guided stereotactic placement of 2 intratumoral catheters on day 0. Patients with histologically confirmed malignant glioma receive interleukin-13 PE38QQR immunotoxin interstitially over 96 hours beginning on day 1. Patients with a residual enhancing mass undergo repeat catheter placement on day 56 and then receive a second interstitial infusion beginning on day 57 in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of interleukin-13 PE38QQR immunotoxin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose-limiting toxicity. Additional patients are treated at the MTD. Patients are followed every 8 weeks. PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for phase I of the study within 6 months and a total of 12-35 patients will be accrued for phase II of the study within 10-12 months.

Eligibility Criteria:

DISEASE CHARACTERISTICS: - Histologically proven malignant glioma (grade 3 or 4) - Anaplastic astrocytoma - Glioblastoma multiforme - Malignant mixed oligoastrocytoma - Must have undergone cranial radiotherapy with tumor dose of at least 48 Gy and at least 12 weeks prior to study - Must have undergone supratentorial brain tumor surgery or biopsy - Must have radiographic evidence of recurrent or progressive supratentorial tumor compared with prior study - Must have solid portion measuring 1.0-5.0 cm in maximum diameter - Maximum of 1 satellite lesion allowed if separated from the primary mass by less than 3 cm - No tumor crossing the midline - No leptomeningeal tumor dissemination - No impending herniation or spinal cord compression - No uncontrolled seizures PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Karnofsky 60-100% Life expectancy: - Not specified Hematopoietic: - Absolute neutrophil count at least 1,500/mm^3 - Hemoglobin at least 10 g/dL - Platelet count at least 100,000/mm^3 Hepatic: - PT and PTT no greater than upper limit of normal (ULN) - SGOT and SGPT no greater than 2.5 times ULN - Bilirubin no greater than 2.0 mg/dL Renal: - Not specified Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No other malignancy within the past 5 years except curatively treated carcinoma in situ or basal cell skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - No prior intralesional chemotherapy for malignant glioma - At least 3 weeks since other prior chemotherapy (6 weeks since prior nitrosoureas) and recovered - No concurrent chemotherapy Endocrine therapy: - Concurrent corticosteroids allowed, but dose must remain stable or be tapered during study Radiotherapy: - See Disease Characteristics - No prior focal radiotherapy (e.g., any form of stereotactic radiotherapy or brachytherapy) for malignant glioma Surgery: - See Disease Characteristics Other: - Recovered from any prior therapy - No other concurrent investigational agent

Study Design:

Study Location:

Multiple U.S. Locations